<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: To assess <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> status by analysis of plasma, erythrocytes and urine in type 1 and type 2 diabetic patients and links to markers of vascular dysfunction </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Diabetic patients (26 type 1 and 48 type 2) with and without <z:mp ids='MP_0002959'>microalbuminuria</z:mp> and 20 <z:mpath ids='MPATH_458'>normal</z:mpath> healthy control volunteers were recruited </plain></SENT>
<SENT sid="2" pm="."><plain>Erythrocyte activity of transketolase, the concentrations of <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> and related phosphorylated metabolites in plasma, erythrocytes and urine, and markers of metabolic control and vascular dysfunction were determined </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Plasma <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> concentration was decreased 76% in type 1 diabetic patients and 75% in type 2 diabetic patients: <z:mpath ids='MPATH_458'>normal</z:mpath> volunteers 64.1 (95% CI 58.5-69.7) nmol/l, type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> 15.3 (95% CI 11.5-19.1) nmol/l, p &lt; 0.001, and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> 16.3 (95% CI 13.0-9.6) nmol/l, p &lt; 0.001 </plain></SENT>
<SENT sid="4" pm="."><plain>Renal clearance of <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> was increased 24-fold in type 1 diabetic patients and 16-fold in type 2 diabetic patients </plain></SENT>
<SENT sid="5" pm="."><plain>Plasma <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> concentration correlated negatively with renal clearance of <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> (r = -0.531, p &lt; 0.001) and fractional excretion of <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> (r = -0.616, p &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Erythrocyte transketolase activity correlated negatively with urinary albumin excretion (r = -0.232, p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="4" ids="26948,33283">Thiamine</z:chebi> transporter protein contents of erythrocyte membranes of type 1 and type 2 diabetic patients were increased </plain></SENT>
<SENT sid="8" pm="."><plain>Plasma <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> concentration and urinary excretion of <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> correlated negatively with soluble vascular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (r = -0.246, p &lt; 0.05, and -0.311, p &lt; 0.01, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: Low plasma <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> concentration is prevalent in patients with type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, associated with increased <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> clearance </plain></SENT>
<SENT sid="10" pm="."><plain>The conventional assessment of <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> status was masked by increased <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> transporter content of erythrocytes </plain></SENT>
</text></document>